Time to Mammographic Density Decrease After Exposure to Tamoxifen

Mammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bäcklund, Magnus, Eriksson, Mikael, Hammarström, Mattias, Thoren, Linda, Bergqvist, Jenny, Margolin, Sara, Hellgren, Roxanna, Wengström, Yvonne, Gabrielson, Marike, Czene, Kamila, Hall, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256030/
https://www.ncbi.nlm.nih.gov/pubmed/35605013
http://dx.doi.org/10.1093/oncolo/oyac104
_version_ 1784741036274221056
author Bäcklund, Magnus
Eriksson, Mikael
Hammarström, Mattias
Thoren, Linda
Bergqvist, Jenny
Margolin, Sara
Hellgren, Roxanna
Wengström, Yvonne
Gabrielson, Marike
Czene, Kamila
Hall, Per
author_facet Bäcklund, Magnus
Eriksson, Mikael
Hammarström, Mattias
Thoren, Linda
Bergqvist, Jenny
Margolin, Sara
Hellgren, Roxanna
Wengström, Yvonne
Gabrielson, Marike
Czene, Kamila
Hall, Per
author_sort Bäcklund, Magnus
collection PubMed
description Mammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg of daily oral tamoxifen. Mammograms were taken at baseline, 3, 6, and 9 months. Mammographic density change was measured using the automated STRATUS tool. Adverse events were monitored through a web-based questionnaire based on the FACT-ES tool. Nine out of the 42 (21%) participants discontinued therapy due to adverse events leaving 33 women in the study. A significant decrease in density was seen after 3 months of therapy. Dose did not seem to affect density change, side effects or adherence. Given the size of the study, additional studies are needed to confirm our data.
format Online
Article
Text
id pubmed-9256030
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92560302022-07-06 Time to Mammographic Density Decrease After Exposure to Tamoxifen Bäcklund, Magnus Eriksson, Mikael Hammarström, Mattias Thoren, Linda Bergqvist, Jenny Margolin, Sara Hellgren, Roxanna Wengström, Yvonne Gabrielson, Marike Czene, Kamila Hall, Per Oncologist Brief Communication Mammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg of daily oral tamoxifen. Mammograms were taken at baseline, 3, 6, and 9 months. Mammographic density change was measured using the automated STRATUS tool. Adverse events were monitored through a web-based questionnaire based on the FACT-ES tool. Nine out of the 42 (21%) participants discontinued therapy due to adverse events leaving 33 women in the study. A significant decrease in density was seen after 3 months of therapy. Dose did not seem to affect density change, side effects or adherence. Given the size of the study, additional studies are needed to confirm our data. Oxford University Press 2022-05-23 /pmc/articles/PMC9256030/ /pubmed/35605013 http://dx.doi.org/10.1093/oncolo/oyac104 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Communication
Bäcklund, Magnus
Eriksson, Mikael
Hammarström, Mattias
Thoren, Linda
Bergqvist, Jenny
Margolin, Sara
Hellgren, Roxanna
Wengström, Yvonne
Gabrielson, Marike
Czene, Kamila
Hall, Per
Time to Mammographic Density Decrease After Exposure to Tamoxifen
title Time to Mammographic Density Decrease After Exposure to Tamoxifen
title_full Time to Mammographic Density Decrease After Exposure to Tamoxifen
title_fullStr Time to Mammographic Density Decrease After Exposure to Tamoxifen
title_full_unstemmed Time to Mammographic Density Decrease After Exposure to Tamoxifen
title_short Time to Mammographic Density Decrease After Exposure to Tamoxifen
title_sort time to mammographic density decrease after exposure to tamoxifen
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256030/
https://www.ncbi.nlm.nih.gov/pubmed/35605013
http://dx.doi.org/10.1093/oncolo/oyac104
work_keys_str_mv AT backlundmagnus timetomammographicdensitydecreaseafterexposuretotamoxifen
AT erikssonmikael timetomammographicdensitydecreaseafterexposuretotamoxifen
AT hammarstrommattias timetomammographicdensitydecreaseafterexposuretotamoxifen
AT thorenlinda timetomammographicdensitydecreaseafterexposuretotamoxifen
AT bergqvistjenny timetomammographicdensitydecreaseafterexposuretotamoxifen
AT margolinsara timetomammographicdensitydecreaseafterexposuretotamoxifen
AT hellgrenroxanna timetomammographicdensitydecreaseafterexposuretotamoxifen
AT wengstromyvonne timetomammographicdensitydecreaseafterexposuretotamoxifen
AT gabrielsonmarike timetomammographicdensitydecreaseafterexposuretotamoxifen
AT czenekamila timetomammographicdensitydecreaseafterexposuretotamoxifen
AT hallper timetomammographicdensitydecreaseafterexposuretotamoxifen

Ejemplares similares